Creel

Creel Bio is a biotechnology company specializing in the development of circular RNA (circRNA) therapeutics to treat a wide range of diseases. By utilizing the unique structural properties of circular RNA, the company aims to create medicines that are more stable and less immunogenic than traditional linear mRNA therapies. Their platform focuses on optimizing the translation and durability of RNA molecules, potentially allowing for lower dosing and longer-lasting therapeutic effects. Creel Bio is currently in the pre-clinical stage, advancing a pipeline of programs primarily focused on oncology and immunology. The company was founded by leading experts in RNA biology, including Howard Chang, and is backed by prominent life science investors.